Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. ^[1] Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology. ^[2] A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. ^[3] Novartis is conducting a thorough review of the observed safety events. ^[4] The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. ^[5] Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value. ^[6] Novartis AG will have exclusive rights, through multiple options, to develop and commercialize SC formulations for multiple products using ALT-B4. ^[7] A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost. ^[8] Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes. ^[9] The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743. ^[10] Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877. ^[11] The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year. ^[12]